You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluphenazine
Accession NumberDB00623  (APRD00633)
TypeSmall Molecule
GroupsApproved
Description

A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. [PubChem]

Structure
Thumb
Synonyms
1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine
10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol
2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol
4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
Flufenazina
Fluorfenazine
Fluorophenazine
Fluorphenazine
Fluphenazin
Fluphénazine
Fluphenazinum
Triflumethazine
External Identifiers
  • SQ 10733
  • Squibb 16144
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluphenazinetablet5 mgoralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazinetablet1 mgoralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazinetablet2 mgoralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazine 1 Tab 1mgtablet1 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 2 Tab 2mgtablet2 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 5 Tab 5mgtablet5 mgoralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine Decanoate Injection B.P.liquid100 mgintramuscular; subcutaneousHospira Healthcare CorporationNot applicableNot applicableCanada
Fluphenazine Decanoate Injection B.P.liquid25 mgintramuscular; subcutaneousHospira Healthcare CorporationNot applicableNot applicableCanada
Fluphenazine Decanoate Injection, USPsolution25 mgintramuscular; subcutaneousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Fluphenazine Omegaliquid100 mgintramuscular; subcutaneousOmega Laboratories Ltd2000-11-20Not applicableCanada
Fluphenazine Omegaliquid25 mgintramuscular; subcutaneousOmega Laboratories Ltd1999-05-28Not applicableCanada
Modecate Concentrateliquid100 mgintramuscular; subcutaneousBristol Myers Squibb Canada1990-12-31Not applicableCanada
Modecate Inj 25mg/mlliquid25 mgintramuscularSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1976-12-312004-08-05Canada
Moditen Enanthate Inj 25mg/mlliquid25 mgintramuscularSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1968-12-312003-07-28Canada
Moditen HCl Tab 10mgtablet10 mgoralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1985-12-312003-07-28Canada
PMS Fluphenazine Tab 1mgtablet1 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS Fluphenazine Tab 2mgtablet2 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS Fluphenazine Tab 5mgtablet5 mgoralPharmascience Inc1992-12-31Not applicableCanada
PMS-fluphenazine Decanoateliquid100 mgintramuscular; subcutaneousPharmascience Inc2000-08-31Not applicableCanada
PMS-fluphenazine Decanoate Inj (bp) 25mg/mlliquid25 mgintramuscular; subcutaneousPharmascience Inc1994-12-31Not applicableCanada
PMS-fluphenazine Elixir 0.5mg/mlelixir.5 mgoralPharmascience Inc1996-10-162008-11-07Canada
Rho-fluphenazine Decanoate Inj-25mg/ml Im Scsolution25 mgintramuscular; subcutaneousRhodiapharm Inc1996-11-282004-07-30Canada
Rho-fluphenazine Decanoate Inj.conc-100mg/mlsolution100 mgintramuscular; subcutaneousRhodiapharm Inc1996-11-282004-07-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Fluphenazine Tab 2.5mgtablet2.5 mgoralApotex Inc1977-12-31Not applicableCanada
Apo-fluphenazine Injectableliquid25 mgintramuscular; subcutaneousApotex Inc2001-10-052013-08-02Canada
Fluphenazine Decanoateinjection, solution25 mg/mLintramuscular; subcutaneousTYA Pharmaceuticals2010-12-15Not applicableUs
Fluphenazine Decanoateinjection, solution25 mg/mLintramuscular; subcutaneousAPP Pharmaceuticals, LLC2010-12-15Not applicableUs
Fluphenazine Decanoateinjection, solution25 mg/mLintramuscular; subcutaneousPar Pharmaceutical, Inc.2014-07-09Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridesolution, concentrate5 mg/mLoralPharmaceutical Associates, Inc.2010-09-01Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2016-04-11Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet1 mg/1oralREMEDYREPACK INC.2011-07-11Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-09-26Not applicableUs
Fluphenazine Hydrochlorideinjection, solution2.5 mg/mLintramuscularAPP Pharmaceuticals, LLC2010-12-28Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1998-07-15Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet2.5 mg/1oralREMEDYREPACK INC.2011-06-03Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralMylan Institutional Inc.1998-06-04Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralMylan Institutional Inc.1998-06-02Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralAmerican Health Packaging2014-10-13Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet1 mg/1oralREMEDYREPACK INC.2011-08-02Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine Hydrochloridetablet, film coated1 mg/1oralMylan Institutional Inc.1998-04-30Not applicableUs
Fluphenazine Hydrochlorideinjection, solution2.5 mg/mLintramuscularTYA Pharmaceuticals2010-12-28Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralSandoz Inc1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluphenazine Hydrochlorideelixir.5 mg/mLoralPharmaceutical Associates, Inc.2010-08-31Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet, film coated5 mg/1oralTYA Pharmaceuticals1987-10-16Not applicableUs
Fluphenazine Hydrochloridetablet, film coated2.5 mg/1oralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2011-10-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnatensolBristol-Myers Squibb
Dapotum DNot Available
FludecasinTanabe Mitsubishi Pharma
FludecateRafa
FlumezinTanabe Mitsubishi Pharma
FunazineJohnson
LyogenLundbeck
Lyogen DepotLundbeck
Lyogen RetardLundbeck
MetotenHemofarm
ModecateBristol-Myers Squibb
ModitenBristol-Myers Squibb
Moditen DepoKrka
PermitilNot Available
ProlixinBristol-Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fluphenazine decanoate
5002-47-1
Thumb
  • InChI Key: VIQCGTZFEYDQMR-UHFFFAOYSA-N
  • Monoisotopic Mass: 591.310632972
  • Average Mass: 591.771
DBSALT000776
Fluphenazine dihydrochloride
146-56-5
Thumb
  • InChI Key: MBHNWCYEGXQEIT-UHFFFAOYSA-N
  • Monoisotopic Mass: 509.128223252
  • Average Mass: 510.443
DBSALT000288
Fluphenazine enanthate
2746-81-8
Thumb
  • InChI Key: LRWSFOSWNAQHHW-UHFFFAOYSA-N
  • Monoisotopic Mass: 549.26368278
  • Average Mass: 549.691
DBSALT000777
Fluphenazine hydrochloride
ThumbNot applicableDBSALT001197
Categories
UNIIS79426A41Z
CAS number69-23-8
WeightAverage: 437.522
Monoisotopic: 437.174867774
Chemical FormulaC22H26F3N3OS
InChI KeyInChIKey=PLDUPXSUYLZYBN-UHFFFAOYSA-N
InChI
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
IUPAC Name
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor management of manifestations of psychotic disorders.
PharmacodynamicsFluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionFluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9837
Blood Brain Barrier+0.975
Caco-2 permeable-0.5387
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.923
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.7669
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7091
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.937
CYP450 3A4 inhibitorNon-inhibitor0.715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7056
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8828
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8990 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9146
hERG inhibition (predictor II)Inhibitor0.8157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Lannett holdings inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral2.5 mg
Injection, solutionintramuscular; subcutaneous25 mg/mL
Elixiroral.5 mg/mL
Injection, solutionintramuscular2.5 mg/mL
Solution, concentrateoral5 mg/mL
Tabletoral1 mg/1
Tabletoral2.5 mg/1
Tabletoral5 mg/1
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral2.5 mg/1
Tablet, film coatedoral5 mg/1
Liquidintramuscular; subcutaneous100 mg
Liquidintramuscular25 mg
Tabletoral10 mg
Tabletoral1 mg
Tabletoral2 mg
Tabletoral5 mg
Liquidintramuscular; subcutaneous25 mg
Elixiroral.5 mg
Solutionintramuscular; subcutaneous25 mg
Solutionintramuscular; subcutaneous100 mg
Prices
Unit descriptionCostUnit
Fluphenazine Omega 100 mg/ml31.2USD ml
Modecate Concentrate 100 mg/ml31.2USD ml
Pms-Fluphenazine Decanoate 100 mg/ml31.2USD ml
Fluphenazine Decanoate 25 mg/ml Solution14.0USD ml
Fluphenazine 2.5 mg/ml vial7.82USD ml
Fluphenazine Omega 25 mg/ml5.22USD ml
Prolixin 10 mg tablet3.1USD tablet
Prolixin 5 mg tablet2.38USD tablet
Fluphenazine dec 25 mg/ml vial1.92USD ml
Prolixin 2.5 mg tablet1.63USD tablet
Fluphenazine 10 mg tablet1.25USD tablet
Fluphenazine HCl 10 mg tablet1.19USD tablet
Fluphenazine 5 mg tablet0.97USD tablet
Fluphenazine HCl 5 mg tablet0.94USD tablet
Fluphenazine 2.5 mg tablet0.84USD tablet
Fluphenazine HCl 2.5 mg tablet0.79USD tablet
Fluphenazine 1 mg tablet0.55USD tablet
Fluphenazine HCl 1 mg tablet0.52USD tablet
Apo-Fluphenazine 2 mg Tablet0.24USD tablet
Apo-Fluphenazine 1 mg Tablet0.18USD tablet
Apo-Fluphenazine 5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point224-226 (Salt)U.S. Patent 3,058,979
boiling point268-274 °C at 5.00E-01 mm HgPhysProp
water solubility31.1 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.36HANSCH,C ET AL. (1995)
logS-4.15ADME Research, USCD
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.019 mg/mLALOGPS
logP4.4ALOGPS
logP3.97ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.27 m3·mol-1ChemAxon
Polarizability44.92 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.44 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-2391100000-6928faa0b341426b2c11View in MoNA
References
Synthesis Reference

Ullyot, G.E.; U.S. Patent 3,058,979; October 16, 1962; assigned to Smith Kline & French
Laboratories.

US3058979
General ReferencesNot Available
External Links
ATC CodesN05AB02
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Fluphenazine can be increased when it is combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Fluphenazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluphenazine.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmisulprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluphenazine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluphenazine.
AmphetamineFluphenazine may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluphenazine.
AzelastineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluphenazine.
BenzphetamineFluphenazine may decrease the stimulatory activities of Benzphetamine.
Botulinum Toxin Type AFluphenazine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BFluphenazine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
BromocriptineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Bromocriptine.
BuprenorphineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluphenazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CathinoneFluphenazine may decrease the stimulatory activities of Cathinone.
Cimetropium BromideFluphenazine may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Fluphenazine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fluphenazine.
CobicistatThe serum concentration of Fluphenazine can be increased when it is combined with Cobicistat.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluphenazine.
DarunavirThe serum concentration of Fluphenazine can be increased when it is combined with Darunavir.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Fluphenazine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluphenazine.
DextroamphetamineFluphenazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluphenazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluphenazine.
DonepezilDonepezil may increase the central neurotoxic activities of Fluphenazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluphenazine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluphenazine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluphenazine.
EluxadolineFluphenazine may increase the activities of Eluxadoline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluphenazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluphenazine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fluphenazine.
EthanolFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluphenazine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluphenazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Fluphenazine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluphenazine.
GalantamineGalantamine may increase the central neurotoxic activities of Fluphenazine.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Glucagon recombinant.
HydrocodoneFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluphenazine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Fluphenazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluphenazine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Fluphenazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Fluphenazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluphenazine.
LisdexamfetamineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Fluphenazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluphenazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Fluphenazine.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluphenazine.
MequitazineFluphenazine may increase the arrhythmogenic activities of Mequitazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluphenazine.
MethamphetamineFluphenazine may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.
MetyrosineFluphenazine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Fluphenazine.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Fluphenazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
MirabegronThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mirabegron.
MirtazapineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluphenazine.
MorphineFluphenazine may increase the hypotensive activities of Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluphenazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluphenazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluphenazine.
OrphenadrineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PanobinostatThe serum concentration of Fluphenazine can be increased when it is combined with Panobinostat.
ParaldehydeFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluphenazine.
PhendimetrazineFluphenazine may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluphenazine.
PhentermineFluphenazine may decrease the stimulatory activities of Phentermine.
PorfimerFluphenazine may increase the photosensitizing activities of Porfimer.
Potassium ChlorideFluphenazine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Fluphenazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluphenazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fluphenazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fluphenazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluphenazine.
PyrimethamineThe serum concentration of Fluphenazine can be increased when it is combined with Pyrimethamine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine.
RamosetronFluphenazine may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluphenazine.
RitonavirThe metabolism of Fluphenazine can be decreased when combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Fluphenazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluphenazine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluphenazine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Fluphenazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluphenazine.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Fluphenazine.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
SulpirideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluphenazine.
SuvorexantFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluphenazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluphenazine.
ThalidomideFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiopentalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiopental.
TiclopidineThe metabolism of Fluphenazine can be decreased when combined with Ticlopidine.
TiotropiumFluphenazine may increase the anticholinergic activities of Tiotropium.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluphenazine.
TopiramateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluphenazine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluphenazine.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Fluphenazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluphenazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Fluphenazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Fluphenazine.
VerteporfinFluphenazine may increase the photosensitizing activities of Verteporfin.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fluphenazine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fluphenazine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluphenazine.
ZolpidemFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402. [PubMed:7508675 ]
  3. Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33. [PubMed:7828655 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Van Kampen JM, Stoessl AJ: Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. 2000;101(3):629-35. [PubMed:11113312 ]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
  4. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Mongin AA, Cai Z, Kimelberg HK: Volume-dependent taurine release from cultured astrocytes requires permissive [Ca(2+)](i) and calmodulin. Am J Physiol. 1999 Oct;277(4 Pt 1):C823-32. [PubMed:10516112 ]
  2. Kawai M, Nakashima A, Ueno M, Ushimaru T, Aiba K, Doi H, Uritani M: Fission yeast tor1 functions in response to various stresses including nitrogen starvation, high osmolarity, and high temperature. Curr Genet. 2001 May;39(3):166-74. [PubMed:11409178 ]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848 ]
  4. Nakabayashi H, Komada H, Yoshida T, Takanari H, Izutsu K: Lymphocyte calmodulin and its participation in the stimulation of T lymphocytes by mitogenic lectins. Biol Cell. 1992;75(1):55-9. [PubMed:1515867 ]
  5. Kauss H: Sensing of volume changes by poterioochromonas involves a ca-regulated system which controls activation of isofloridoside-phosphate synthase. Plant Physiol. 1981 Aug;68(2):420-4. [PubMed:16661928 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 23, 2014 17:18